Alert

Recommended Alerts

Sign Up For Alerts

Private Equity Firm Settles with DOJ in False Claims Act Matter Based on Claims Submitted by Its Health Care Portfolio Company

Compounding pharmacy Diabetic Care Rx, LLC d/b/a Patient Care America (“PCA”), two individual executives, and the pharmacy’s private equity fund owner, Riordan, Lewis & Haden, Inc. (“RLH”) recently reached a $21 million settlement with the U.S. Department of Justice (“DOJ”) to resolve allegations that the parties engaged in an illegal kickback scheme resulting in submission of false claims to the government in violation of the False Claims Act (“FCA”).

Read More

Senator Chuck Grassley Presses Comptroller General to Investigate Foreign Threats to Taxpayer-Funded Research


Time to Read: 1 minutes Practices: Health Care

Printer-Friendly Version

On Tuesday, Senate Finance Committee Chairman Chuck Grassley of Iowa sent a letter to the General Accountability Office asking it to examine “how federal agencies implement and oversee conflict-of-interest policies and requirements related to federally funded research,” with special attention to diversity across federal agency and nonfederal institutional research policies, including monitoring and enforcement, and requirements for disclosing foreign affiliations. The letter follows from a June Finance Committee hearing and multiple oversight letters from Senator Grassley in the last year, all focused on foreign threats and perceived threats to research funded by federal agencies like the National Institutes of Health, the National Science Foundation, and the Department of Defense, among others. Of note, and as is common in these types of GAO request letters, there is a specific request for GAO to consult stakeholders, including research institutions and principal investigators, to learn their views about “options to strengthen federal agencies’ and nonfederal institutions’ ability to identify and address foreign threats to federally funded research.” For example, the letter asks about the possibility of making “changes to grant forms that place more responsibility for financial disclosures on principal investigators.”

While GAO is not legally bound to begin this inquiry, it may be expected to do so given the source of the request and the timeliness of the topic. Notwithstanding this uncertainty, and the fact the GAO reviews can often take years to complete, universities, academic medical centers, and others receiving federal research dollars should be aware of the request and attend to its terms and progress, and to the Senate’s interest in the topic. For example, the reference to changing grant forms to place more responsibility on PIs signals current thinking on actions that Congress might take to address its concerns about undue foreign influence in taxpayer-funded research.

The letter and press release describing it can be found here.

Printer-Friendly Version

Cookie Settings